Potential mechanisms of anaphylaxis to COVID-19 mRNA vaccines.

"Disclosure of potential conflict of interest: All authors have served as consultants to the Centers for Disease Control and Prevention (CDC)-sponsored Clinical Immunization Safety Assessment (CISA) Project. This work was not supported by CISA. K. M. Edwards has grant funding from the CDC and is a consultant for IBM and Bionet and a member of the data safety and monitoring boards for Pfizer, Sanofi, Moderna, Seqirus, CEPI, Merck, X-4 Pharma, and Roche. A. Stallings has support from Regeneron Pharmaceuticals. R. A. Wood, F. F. Little, K. M. Edwards, and J. D. Milner have grant funding from the National Institutes of Health. J. D. Milner is providing expert witness testimony on trauma and hypersensitivity. R. A. Wood receives research support from Aimmune, Astellas, DBV, HAL-Allergy, Genentech, Regeneron, and Sanofi, and royalties from Up To Date. A. E. Norton and K. A. Risma have no external funding sources to declare."

"Disclosure of potential conflict of interest: All authors have served as consultants to the Centers for Disease Control and Prevention (CDC)-sponsored Clinical Immunization Safety Assessment (CISA) Project. This work was not supported by CISA. K. M. Edwards has grant funding from the CDC and is a consultant for IBM and Bionet and a member of the data safety and monitoring boards for Pfizer, Sanofi, Moderna, Seqirus, CEPI, Merck, X-4 Pharma, and Roche. A. Stallings has support from Regeneron Pharmaceuticals. R. A. Wood, F. F. Little, K. M. Edwards, and J. D. Milner have grant funding from the National Institutes of Health. J. D. Milner is providing expert witness testimony on trauma and hypersensitivity. R. A. Wood receives research support from Aimmune, Astellas, DBV, HAL-Allergy, Genentech, Regeneron, and Sanofi, and royalties from Up To Date. A. E. Norton and K. A. Risma have no external funding sources to declare."